Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Study to Investigate Steady State Semaglutide Exposure of a New Formulation of Oral Semaglutide in Healthy Participants

NCT05784402 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT05784402
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05784402 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Study to Investigate Steady State Semaglutide Exposure of a New Formulation of Oral Semaglutide in Healthy Participants
Lead sponsor
Novo Nordisk A/S
Phase
Phase 1
Overall status
Completed
Start date
March 16, 2023
Completion date
March 29, 2024
Enrollment
264 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants